NCT04385095 - Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection | Biotech Hunter

Enrollment

221

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

February 17, 2021

Study Completion Date

November 16, 2021

Conditions

SARS-CoV-2

Interventions

DRUG

SNG001

SNG001 via inhalation

DRUG

Placebo

Placebo via inhalation

Trial Locations (13)

BT9 7AB

Belfast City Hospital, Belfast

B15 2GW

Queen Elizabeth Hospital,, Birmingham

BD9 6RJ

Bradford Royal Infirmary, Bradford

SO53 4ST

Park and St Francis Surgery, Chandler's Ford

HU16 5JQ

Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull

LE3 9QP

Glenfield Hospital,, Leicester

M23 9LT

Wythenshawe Hospital, Manchester

NG5 1PB

City Campus of Nottingham University, Nottingham

OX3 9DU

John Radcliffe Hospital, Oxford

BH15 2HX

The Adam Practice, Poole

SO16 6YD

The Virtual Team, Southampton

University Hospital Southampton Nhs Foundation Trust, Southampton

PO8 8DL

Oaks Healthcare, Waterlooville

All Listed Sponsors

lead

Synairgen Research Ltd.

INDUSTRY